跳至主要内容
临床试验/NCT05581992
NCT05581992已完成1 期

An Open-label Study to Evaluate the Drug-drug Interaction Effect of Omeprazole, a Proton-pump Inhibitor, on the Pharmacokinetics of AMG 510 in Healthy Subjects

Amgen1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2020年1月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Amgen
入组人数
14
试验地点
1
主要终点
Maximum Observed Plasma Concentration (Cmax) of AMG 510

研究概览

简要总结

The primary objective of this study is to evaluate the PK profile of AMG 510 alone and in combination with omeprazole in healthy participants.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male subjects or female participants, between 18 and 60 years of age (inclusive), at the time of Screening.
  • Body mass index, between 18 and 30 kg/m2 (inclusive), at the time of Screening.
  • Females of nonchildbearing potential.

排除标准

  • Inability to swallow oral medication or history of malabsorption syndrome.
  • History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
  • Poor peripheral venous access.
  • History or evidence, at Screening or Check in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

研究组 & 干预措施

AMG 510 + Omeprazole

Experimental

Participants will receive AMG 510 on Day 1, daily doses of omeprazole on Days 4 to 8, and a single dose of both omeprazole and AMG 510 on Day 9.

干预措施: AMG 510 (Drug)

AMG 510 + Omeprazole

Experimental

Participants will receive AMG 510 on Day 1, daily doses of omeprazole on Days 4 to 8, and a single dose of both omeprazole and AMG 510 on Day 9.

干预措施: Omeprazole (Drug)

结局指标

主要结局

Maximum Observed Plasma Concentration (Cmax) of AMG 510

时间窗: Day 1 and Day 9

Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 510

时间窗: Day 1 and Day 9

AUC from time Zero to Infinity (AUCinf) of AMG 510

时间窗: Day 1 and Day 9

次要结局

  • Number of Participants with an Adverse Event (AE)(Day 1 to Day 11)

研究者

发起方
Amgen
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Study to Evaluate the Drug-drug Interaction Effect... | 临床试验